Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCA-136 in Acute Exacerbations of Schizophrenia
NCT00265551Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vabicaserin in schizophrenia (4 arms), sponsored by Pfizer. Primary endpoint: Structured Clinical Interview for the Positive and Negative Syndrome Scale - Positive Subscale at Day 42. Started Jan 2006; status: completed.
02
Drugs
vabicaserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00265551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265551.